Intrahepatic Cholangiocarcinoma
Conditions
Brief summary
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
Interventions
DRUGHMPL-453
300 mg HMPL-453
DRUGRabeprazole
20 mg of rabeprazole will be administered by mouth once daily.
Sponsors
Hutchmed
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label, 4-Period, Randomized 6-Sequence Study
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Have fully understood the study and voluntarily signed the informed consent form; 2. The volunteer is male or female between the ages of 18 and 55 years old (inclusive) at the time of informed consent. 3. The volunteer has a body mass index (BMI)\>18 and ≤29.9 kg/m2at screening. Male need≥50 kg，famele need≥45 kg. 4. Female with fertility agree to adopt efficient contraceptive measures within 6 months after signing ICF until the end of the last HMPL-453 dosing, and agree not to donate eggs (or oocytes) for reproductive purposes during this period. Acceptable and efficient contraceptive methods include complete abstinence, bilateral tubal ligation, oral or injection contraceptives, intrauterine devices, or partner vas deferens ligation. All hormonal contraception measures must be combined with barrier measures such as the use of condoms by spouses. More information can be found in Attachment 12.3 \[Definition of Women with Fertility (WOCBP) and Acceptable and Unacceptable Contraceptive Methods\]. 5. Male patients is willing to take contraception measures (during the study and for 3 months after the end of study treatment). Male patients should avoid donating or freezing sperm during this period. 6. The volunteer is willing and able to comply with all aspects of the protocol.
Exclusion criteria
1. The volunteer has a known history of any gastrointestinal surgery or any condition possibly affecting drug absorption (eg, cholecystectomy, gastrectomy, achlorhydria, peptic ulcer disease, or history of stomach or intestinal surgery or resection). 2. The volunteer had a clinically significant illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose. 3. The volunteer has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or at Day -1 check-in (baseline). 4. The volunteer has systolic blood pressure \>140 mmHg diastolic blood pressure \>90mmHg. 5. Currently keratopathy confirmed by ophthalmological examination, including but not limited to bullae keratopathy, zonal corneal degenerations, corneal abrasion, corneal ulcer, and sclerokeratitis. 6. Current or prior history of retinal detachment. 7. The volunteer has a clinically significant ECG abnormality, including a marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTcF interval \>480msec), or hasa family history of prolonged QTc syndrome or sudden death. 8. Volunteers who smoke more than 10 cigarettes per day within the first 3 months of screening and are unable to completely quit smoking during the study period. 9. Volunteers who frequently drink alcohol within the first 6 months before screening, drink more than 14 units of alcohol per week。 10. The volunteer has a history of drug misuse within 6 months prior to screening (including those who have tested positive for morphine, methylenedioxymethamphetamine, methamphetamine, tetrahydrocannabinol acid, ketamine, cocaine, or a positive urine drug test at screening or at check-in). 11. The volunteer has been diagnosed with acquired immune deficiency syndrome or has performed tests that are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV). 12. The volunteer has a clinically significant X-ray, 13. The volunteer has participated in a clinical trial of other study drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the volunteer is currently enrolled in another clinical trial. 14. The volunteer has used CYP3A strong inducer or strong inhibitor, any over-the-counter (OTC) medications or prescription drugs (medications that can lower gastric acid in particular) within 2 weeks prior to the first dose. 15. The volunteer has consumed alcohol, grapefruit, lime, and caffeine within 72 hours prior to the first dose. 16. Taking drugs or dietary supplements (such as calcium, phosphorus, vitamin D, parathyroid hormone, etc.) that may cause blood phosphorus and/or blood calcium to rise within 2 weeks prior to the start of the study treatment. 18.Needle sickness, blood sickness or difficulty in collecting venous blood. 19.The volunteer is allergic to any of the study drugs (or its excipients) to be given in this study. 20.A female participant is pregnant, lactating, or breastfeeding. 21.Any other medical condition judged by the investigator would make the patients unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK parameter for HMPL-453: AUC0-t | Day 1 to Day 33 | Area under the concentration time curve from time 0 to the last measurable concentration |
| PK parameter for HMPL-453: AUC0-inf | Day 1 to Day 33 | Area under the concentration time curve from time 0 extrapolated to infinity |
| PK parameter for HMPL-453: Cmax | Day 1 to Day 33 | Maximum observed plasma concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of safety procedures findings | Day 1 to Day 33 | Any untoward medical occurrence associated with the study drug |
| PK parameter for HMPL-453: tmax,t1/2 | Day 1 to Day 33 | Time to reach the maximum observed plasma concentration, elimination half-life |
Countries
China
Outcome results
None listed